tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2020 Aug 24;88:106928.
doi: 10.1016/j.intimp.2020.106928. Online ahead of print.
Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
Rasoul Mirzaei[SUP] 1 [/SUP], Rokhsareh Mohammadzadeh[SUP] 2 [/SUP], Farzad Mahdavi[SUP] 3 [/SUP], Fariba Badrzadeh[SUP] 4 [/SUP], Sheida Kazemi[SUP] 5 [/SUP], Mehdi Ebrahimi[SUP] 6 [/SUP], Fatemeh Soltani[SUP] 7 [/SUP], Sima Kazemi[SUP] 8 [/SUP], Ali Salimi Jeda[SUP] 9 [/SUP], Mohammad Darvishmotevalli[SUP] 10 [/SUP], Rasoul Yousefimashouf[SUP] 8 [/SUP], Hossein Keyvani[SUP] 11 [/SUP], Sajad Karampoor[SUP] 12 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by the novel coronavirus called SARS-CoV-2. There is a gap in our understanding regarding the immunopathogenesis of COVID-19. However, many clinical trials are underway across the world for screening effective drugs against COVID-19. Nevertheless, currently, no proven effective therapies for this virus exists. The vaccines are deemed as a significant part of disease prevention for emerging viral diseases, since, in several cases, other therapeutic choices are limited or non-existent, or that diseases result in such an accelerated clinical worsening that the efficacy of treatments is restricted. Therefore, effective vaccines against COVID-19 are urgently required to overcome the tremendous burden of mortality and morbidity correlated with SARS-CoV-2. In this review, we will describe the latest evidence regarding outstanding vaccine approaches and the challenges for vaccine production.
Keywords: COVID-19; Immunopathogenesis; SARS-CoV-2; Vaccines.
. 2020 Aug 24;88:106928.
doi: 10.1016/j.intimp.2020.106928. Online ahead of print.
Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
Rasoul Mirzaei[SUP] 1 [/SUP], Rokhsareh Mohammadzadeh[SUP] 2 [/SUP], Farzad Mahdavi[SUP] 3 [/SUP], Fariba Badrzadeh[SUP] 4 [/SUP], Sheida Kazemi[SUP] 5 [/SUP], Mehdi Ebrahimi[SUP] 6 [/SUP], Fatemeh Soltani[SUP] 7 [/SUP], Sima Kazemi[SUP] 8 [/SUP], Ali Salimi Jeda[SUP] 9 [/SUP], Mohammad Darvishmotevalli[SUP] 10 [/SUP], Rasoul Yousefimashouf[SUP] 8 [/SUP], Hossein Keyvani[SUP] 11 [/SUP], Sajad Karampoor[SUP] 12 [/SUP]
Affiliations
- PMID: 32862110
- DOI: 10.1016/j.intimp.2020.106928
Abstract
Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by the novel coronavirus called SARS-CoV-2. There is a gap in our understanding regarding the immunopathogenesis of COVID-19. However, many clinical trials are underway across the world for screening effective drugs against COVID-19. Nevertheless, currently, no proven effective therapies for this virus exists. The vaccines are deemed as a significant part of disease prevention for emerging viral diseases, since, in several cases, other therapeutic choices are limited or non-existent, or that diseases result in such an accelerated clinical worsening that the efficacy of treatments is restricted. Therefore, effective vaccines against COVID-19 are urgently required to overcome the tremendous burden of mortality and morbidity correlated with SARS-CoV-2. In this review, we will describe the latest evidence regarding outstanding vaccine approaches and the challenges for vaccine production.
Keywords: COVID-19; Immunopathogenesis; SARS-CoV-2; Vaccines.